See more : National Plastic Industries Limited (NATPLAS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Apollo Endosurgery, Inc. (APEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apollo Endosurgery, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Johnson Service Group PLC (JSG.L) Income Statement Analysis – Financial Results
- PharmaRoth Labs, Inc. (ROTH) Income Statement Analysis – Financial Results
- Mobiquity Technologies, Inc. (MOBQW) Income Statement Analysis – Financial Results
- American Financial Group, Inc. (AFGE) Income Statement Analysis – Financial Results
- Y’s Table Corporation (2798.T) Income Statement Analysis – Financial Results
Apollo Endosurgery, Inc. (APEN)
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.86M | 62.99M | 42.05M | 50.71M | 60.85M | 64.31M | 64.87M | 1.60M | 5.08M | 7.99M | 6.69M | 9.39M | 7.84M | 11.91M | 2.86M | 372.35K | 511.86K | 743.27K |
| Cost of Revenue | 34.43M | 28.03M | 19.81M | 25.04M | 27.66M | 24.58M | 25.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 42.43M | 34.96M | 22.24M | 25.68M | 33.19M | 39.73M | 39.61M | 1.60M | 5.08M | 7.99M | 6.69M | 9.39M | 7.84M | 11.91M | 2.86M | 372.35K | 511.86K | 743.27K |
| Gross Profit Ratio | 55.20% | 55.50% | 52.90% | 50.63% | 54.55% | 61.78% | 61.07% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 11.91M | 9.52M | 7.67M | 10.38M | 12.18M | 8.30M | 7.81M | 8.51M | 18.13M | 11.34M | 8.16M | 9.73M | 7.82M | 6.63M | 10.12M | 12.42M | 4.04M | 1.48M |
| General & Administrative | 20.58M | 18.45M | 11.06M | 13.59M | 13.44M | 13.72M | 13.63M | 3.95M | 4.76M | 4.23M | 4.09M | 0.00 | 4.50M | 3.48M | 4.48M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 36.01M | 24.31M | 17.36M | 28.73M | 32.83M | 32.91M | 31.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 56.59M | 42.76M | 28.42M | 42.32M | 46.27M | 46.63M | 45.38M | 3.95M | 4.76M | 4.23M | 4.09M | 3.37M | 4.50M | 3.48M | 4.48M | 3.43M | 2.23M | 1.66M |
| Other Expenses | 1.75M | 1.88M | 1.95M | 2.10M | 7.07M | 7.24M | 7.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 70.25M | 54.16M | 38.04M | 54.80M | 65.52M | 62.17M | 60.37M | 12.46M | 22.89M | 15.58M | 12.25M | 13.10M | 12.32M | 10.11M | 14.60M | 15.85M | 6.28M | 3.15M |
| Cost & Expenses | 104.68M | 82.19M | 57.84M | 79.84M | 93.18M | 86.75M | 85.63M | 12.46M | 22.89M | 15.58M | 12.25M | 13.10M | 12.32M | 10.11M | 14.60M | 15.85M | 6.28M | 3.15M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 124.04K | 398.02K | 161.24K | 7.95K |
| Interest Expense | 4.67M | 8.32M | 5.25M | 4.05M | 4.06M | 4.51M | 18.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.12K | 27.95K | 0.00 | 157.13K |
| Depreciation & Amortization | -196.00K | 2.01M | 2.31M | 2.50M | 9.29M | 9.72M | 9.09M | 466.99K | 216.09K | 196.22K | 187.50K | 141.99K | 165.30K | 176.69K | 215.02K | 156.44K | 49.57K | 81.18K |
| EBITDA | -31.42M | -17.19M | -13.49M | -26.62M | -40.09M | -12.76M | -20.76M | -9.54M | -17.81M | -7.59M | -5.56M | -2.97M | 0.00 | 0.00 | -11.23M | -15.48M | -5.56M | -2.40M |
| EBITDA Ratio | -36.46% | -27.28% | -32.08% | -52.49% | -52.98% | -19.85% | -20.84% | -596.55% | -321.60% | -79.74% | -38.35% | -31.66% | -56.62% | 34.93% | -392.60% | -4,003.61% | -1,085.29% | -344.22% |
| Operating Income | -27.82M | -19.20M | -15.79M | -29.12M | -40.09M | -22.44M | -20.76M | -10.86M | -17.81M | -7.59M | -5.56M | -3.71M | -4.49M | 1.80M | -11.74M | -15.48M | -5.77M | -2.40M |
| Operating Income Ratio | -36.20% | -30.48% | -37.56% | -57.43% | -65.88% | -34.89% | -32.00% | -678.87% | -350.46% | -95.05% | -83.16% | -39.52% | -57.29% | 15.13% | -410.16% | -4,156.30% | -1,126.47% | -323.39% |
| Total Other Income/Expenses | -7.83M | -5.33M | -6.68M | 1.97M | -5.50M | -4.55M | -20.02M | 850.05K | 1.25M | 1.03M | 2.81M | 595.91K | -113.38K | 2.18M | 163.33K | 384.12K | 0.00 | -402.84K |
| Income Before Tax | -39.26M | -24.53M | -22.47M | -27.16M | -45.60M | -26.99M | -40.78M | -10.01M | -16.56M | -6.56M | -2.75M | -3.11M | -4.60M | 3.98M | -11.57M | -15.46M | 0.00 | -2.65M |
| Income Before Tax Ratio | -51.08% | -38.94% | -53.44% | -53.55% | -74.93% | -41.97% | -62.87% | -625.74% | -325.86% | -82.19% | -41.15% | -33.18% | -58.73% | 33.44% | -404.45% | -4,152.52% | 0.00% | -356.21% |
| Income Tax Expense | 584.00K | 156.00K | 142.00K | 275.00K | 191.00K | 304.00K | 387.00K | 850.05K | 1.25M | 1.03M | 2.81M | 595.91K | -113.38K | 2.18M | 175.45K | 42.00K | 0.00 | -86.79K |
| Net Income | -39.84M | -24.68M | -22.61M | -27.43M | -45.79M | -27.29M | -41.17M | -10.01M | -16.56M | -6.56M | -2.75M | -3.11M | -4.60M | 3.98M | -11.46M | -15.09M | -5.60M | -2.80M |
| Net Income Ratio | -51.84% | -39.18% | -53.77% | -54.09% | -75.24% | -42.44% | -63.46% | -625.74% | -325.86% | -82.19% | -41.15% | -33.18% | -58.73% | 33.44% | -400.54% | -4,053.13% | -1,094.97% | -376.28% |
| EPS | -0.98 | -0.82 | -0.99 | -1.27 | -2.31 | -2.01 | -105.69 | -29.95 | -77.00 | -37.61 | -19.74 | -26.65 | -44.48 | 39.63 | -128.50 | -209.81 | -123.52 | -365.69 |
| EPS Diluted | -0.98 | -0.82 | -0.99 | -1.27 | -2.31 | -2.01 | -105.69 | -29.95 | -77.00 | -37.61 | -19.74 | -26.65 | -44.48 | 37.78 | -128.50 | -209.81 | -123.52 | -365.69 |
| Weighted Avg Shares Out | 40.65M | 30.24M | 22.76M | 21.54M | 19.79M | 13.57M | 389.50K | 334.22K | 215.01K | 174.53K | 139.44K | 116.83K | 103.46K | 100.52K | 89.18K | 71.93K | 45.38K | 7.65K |
| Weighted Avg Shares Out (Dil) | 40.65M | 30.24M | 22.76M | 21.54M | 19.79M | 13.57M | 389.50K | 334.22K | 215.01K | 174.53K | 139.44K | 116.83K | 103.46K | 105.43K | 89.18K | 71.93K | 45.38K | 7.65K |
Apollo Endosurgery, Inc. Reports 29% Increase in First Quarter Revenue
Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m.
APEN Stock: From $5.59 To $5.81 (3.94% Increase) Pre-Market Explanation
The stock price of Apollo Endosurgery Inc (NASDAQ: APEN) increased from $5.59 to $5.81 pre-market. This is why it happened.
Apollo Endosurgery to Report First Quarter Financial Results on May 4, 2021
AUSTIN, TX / ACCESSWIRE / April 28, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results...
Will Apollo Endosurgery, Inc. (APEN) Report Negative Q1 Earnings? What You Should Know
Apollo Endosurgery, Inc. (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apollo Endosurgery Announces Publication of Pre-Clinical Results for X-Tack(TM) Endoscopic HeliX Tacking System
Authors conclude, " Compared to TTS clip, X-Tack is superior for effecting large mucosal defect closure, including durable sealing of full-thickness perforation. " AUSTIN, TX / ACCESSWIRE / April 21, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader...
Apollo Endosurgery Announces Inducement Grant
AUSTIN, TX / ACCESSWIRE / March 19, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the terms of equity awards granted to Chas McKhann in connection with...
Apollo Endosurgery announces AMA assignment of Category I CPT Codes for use in Intragastric Balloon Procedures
AUSTIN, TX / ACCESSWIRE / March 8, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the assignment of Category I Current Procedural Terminology (CPT®) codes with short...
Apollo Endosurgery to Present at HC Wainwright Global Life Sciences Conference
AUSTIN, TX / ACCESSWIRE / March 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it will participate in the H.C. Wainwright Global Life Sciences...
APEN Stock Price Increases Over 55% Pre-Market: Why It Happened
The stock price of Apollo Endosurgery Inc (NASDAQ: APEN) is trading at over 55% pre-market. This is why it happened.
Apollo Endosurgery, Inc. (APEN) CEO Todd Newton on Q4 2020 Results - Earnings Call Transcript
Apollo Endosurgery, Inc. (APEN) CEO Todd Newton on Q4 2020 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports